Case series of complex therapy of hemoblastosis in the context of COVID-19

Case series of complex therapy of hemoblastosis in the context of COVID-19

Blog Article

Introduction: The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology.Patients with cancer are at high risk of getting infected with COVID-19.Diagnosis of coronavirus infection in such patients entails the cancellation of chemotherapy for an indefinite period.

A break between courses of treatment, as arcade smokey the bear belt well as a complete cancellation of therapy, can increase the mortality of patients from oncohematological diseases.Material and methods: From June to October 2020, based on the Oncohematological Department of the National Research Oncology Center LLP, 19 patients were treated, of which: men - 11, women - 8.Average age - 43 years (+ -16).

Of these, patients with multiple myeloma - 32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%.Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection.Results: This article opi the color that keeps on giving presents clinical cases of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection who were treated in a hospital.